文献速递乳腺癌

爱尔兰乳腺癌雌激素受体特异性趋势 diverging(2004-2013):来自独立西方人群的数据为病因学提供线索

Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): Amassing data from independent Western populations provide etiologic clues.
PubMed 文献 · Eur J Cancer · 2017-10-23

该研究基于爱尔兰国家癌症登记处2004-2013年24,845例浸润性乳腺癌数据,分析雌激素受体(ER)及ER/HER2联合表达的特异性年龄标化发病率趋势。结果显示ER+癌症年龄标化发病率每年上升2.2%(95%CI 0.97-3.45%/年),ER-癌症每年下降3.43%(95%CI -5.05至-1.78%/年),ER+/HER2-上升,ER+/HER2+统计持平,ER-/HER±下降。按HER2分层未实质改变ER趋势。

要点

  • ER+乳腺癌年龄标化发病率每年上升2.2%(95%CI 0.97-3.45%/年)。
  • ER-乳腺癌年龄标化发病率每年下降3.43%(95%CI -5.05至-1.78%/年)。
  • ER+/HER2-上升,ER+/HER2+统计持平,ER-/HER±下降;HER2分层未实质改变ER趋势。

核心结论

  • 爱尔兰ER+与ER-乳腺癌发病率趋势 diverging,与先前美国、丹麦观察一致,可能反映日历时期和/或风险因素变化对ER+和ER-乳腺癌的差异效应。

研究设计与样本

  • 基于爱尔兰国家癌症登记处的基于人群研究,纳入2004-2013年浸润性乳腺癌24,845例,风险人群来自爱尔兰中央统计局(n=10,401,986)。
  • 采用估计年度百分比变化(EAPC)及95%置信区间评估年龄标化发病率的受体特异性趋势,并拟合年龄-时期-队列模型。

主要发现

  • ER+癌症年龄标化发病率每年上升2.2%(95%CI 0.97-3.45%/年),ER-癌症每年下降3.43%(95%CI -5.05至-1.78%/年)。
  • 在诊断年龄<30-49、50-64和≥65岁特定年龄组中,ER+上升、ER-下降。
  • ER+/HER2-癌症上升,ER+/HER2+癌症统计持平,ER-/HER±癌症下降。
  • 按HER2±表达分层未实质改变ER±趋势。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aetiology and clinical behaviour of breast cancers vary by oestrogen receptor (ER) expression, HER2 expression and over time. Data from the United States and Denmark show rising incidence rates for ER+ and falling incidence rates for ER- breast cancers. Given that Ireland is a somewhat similar Western population but with distinctive risk exposures (especially for lactation), we analysed breast cancer trends by ER status; and for the first time, by the joint expression of ER±/HER2±. We assessed invasive breast cancers (n = 24,845; 2004-2013) within the population-based National Cancer Registry of Ireland. The population at risk was obtained from the Irish Central Statistics Office (n = 10,401,986). After accounting for missing ER and HER2 data, we assessed receptor-specific secular trends in age-standardised incidence rates (ASRs) with the estimated annual percentage change (EAPC) and corresponding 95% confidence intervals (95% CI). Age-period-cohort models were also fitted to further characterise trends accounting for age, calendar-period and birth-cohort interactions. ASRs increased for ER+ (EAPC: 2.2% per year [95% CI: 0.97, 3.45%/year]) and decreased for ER- cancers (EAPC: -3.43% per year [95% CI: -5.05, -1.78%/year]), as well as for specific age groups at diagnosis (<30-49, 50-64 and ≥65 years). ER+/HER2- cancers rose, ER+/HER2+ cancers were statistically flat and ER-/HER± cancers declined. Secular trends for ER± cancers in Ireland were like those previously observed. Stratification by HER2± expression did not substantively alter ER± trends. The divergence of ER± incidence rates among independent Western populations likely reflects calendar-period and/or risk factor changes with differential effects for ER+ and ER- breast cancers.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mullooly M, Murphy J, Gierach GL, et al. Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): Amassing data from independent Western populations provide etiologic clues. Eur J Cancer. 2017. PMID: 29073583. doi:10.1016/j.ejca.2017.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。